Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference
July 31, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares
June 05, 2018 12:49 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, June 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting
June 04, 2018 09:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares
June 01, 2018 09:13 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Listing on Nasdaq Capital Market
June 01, 2018 07:40 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Public Offering of Common Shares
May 31, 2018 16:27 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYD), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces New OTCQX Ticker Symbol
May 29, 2018 12:05 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYD), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone
May 25, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 25, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Has Applied to List its Common Shares on Nasdaq and Announces Share Consolidation
May 22, 2018 17:13 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study
May 17, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...